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Abstract Novel psychoactive substances are continuously
developed to circumvent legislative and regulatory efforts. A
new synthetic cathinone, 4-methoxy-a-PVP, was identified for
the first time in illegal products; however, the metabolism of
this compound is not known. Complete metabolic profiles are
needed for these novel psychoactive substances to enable
identification of their intake and to link adverse effects to the
causative agent. This study assessed 4-methoxy-a-PVP
metabolic stability with human liver microsomes (HLMs) and
identified its metabolites after HLM and hepatocyte incuba-
tions followed by high-resolution mass spectrometry (HRMS).
A Thermo QExactive high-resolution mass spectrometer
(HRMS) was used with full scan data-dependent mass spec-
trometry, with (1) and without (2) an inclusion list of predicted
metabolite, and with full scan and all-ion fragmentation (3) to
identify potential unexpected metabolites. In silico predictions
were performed and compared to in vitro results. Scans were
thoroughly mined with different data processing algorithms
using WebMetabase (Molecular Discovery). 4-Methoxy-a-
PVP exhibited a long half-life of 79.7 min in HLM, with an
intrinsic clearance of 8.7 lL min-1 mg-1. In addition, this
compound is predicted to be a low-clearance drug with an
estimated human hepatic clearance of 8.2 mL min-1 kg-1.
Eleven 4-methoxy-a-PVP metabolites were identified, gener-
ated by O-demethylation, hydroxylation, oxidation, ketone
reduction, N-dealkylation, and glucuronidation. The most
dominant metabolite in HLM and human hepatocyte samples
was 4-hydroxy-a-PVP, also predicted as the #1 in silico
metabolite, and is suggested to be a suitable analytical target in
addition to the parent compound.
Keywords 4-Methoxy-a-PVP  Novel psychoactive
substances  Synthetic cathinones  Human hepatocytes 
Human liver microsomes  In silico prediction
Introduction
In recent years, novel psychoactive substances (NPSs)
appeared rapidly on the drug market in an effort to bypass
controlled substance legislation. The European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) reported
41 NPSs identified for the first time across Europe in 2010,
81 in 2013, and 101 in 2014 [1]. These NPSs are contin-
uously developed to circumvent legislative and regulatory
efforts, with limited available pharmacological and toxi-
cological data. NPSs encompass a wide range of com-
pounds including synthetic cannabinoids, phenethylamines,
tryptamines, piperazines, ketamine, cathinones, and other
plant-based psychoactive substances [2].
Synthetic cathinones emerged on the designer drug
market as popular ‘‘legal’’ alternatives to illicit drugs in the
late 2000s, and are marketed as ‘‘legal highs’’ and ‘‘not for
human consumption’’. They are stimulant-like drugs
derived from cathinone, the active ingredient of the khat
plant Catha edulis, with adverse effects including hyper-
thermia, agitation, confusion, psychosis, seizures, and
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tachycardia [3–7]. A variety of synthetic cathinones, alone
and in combination with other illicit drugs, were detected
in acute intoxications [4, 8, 9], impaired driving cases [10–
13], and fatalities [4, 12, 14–23].
4-Methoxy-a-PVP (4-methoxy-a-pyrrolidinovalerophe-
none) was identified for the first time in illegal products
purchased in Japan in 2013 [24] and also recently identified
by Customs in Berlin [25]. 4-Methoxy-a-PVP is a substi-
tuted cathinone containing a pyrrolidinyl moiety and a
methoxy group on the 40 position of the aromatic ring
(Fig. 1). Its structure is similar to other a-pyrrolidinophe-
none derivatives such as 3,4-methylenedioxypyrovalerone
(MDPV) and a-pyrrolidinovalerophenone (a-PVP), both
schedule I compounds [26, 27]. The mechanism of action
of 4-methoxy-a-PVP is unknown; however, based on
structural similarities to MDPV and a-PVP, it is hypothe-
sized that 4-methoxy-a-PVP would act similarly as a
monoamine transporter blocker increasing the amount of
extracellular dopamine [28–31]. Extracellular dopamine
increases pose a higher risk for addiction [28, 31]. In
addition, the high lipophilicity of the pyrrolidine ring
increases permeability through the blood–brain barrier, and
hence increased potency and abuse potential [29, 32, 33].
The metabolic pathways of other a-pyrrolidinophenones,
including MDPV, a-PVP, a-pyrrolidinobutiophenone
(a-PBP), a-pyrrolidinopropiophenone (a-PPP), 4-methyl-
a-pyrrolidinopropiophenone (MPPP), and 4-methoxy-a-
pyrrolidinopropiophenone (MOPPP), were previously
investigated [34–42]. There are no metabolism studies for
4-methoxy-a-PVP. A recent review of the pharmacology of
a-pyrrolidinophenones outlined the major metabolic path-
ways of other structurally similar compounds including
reduction of the keto moiety to the corresponding alcohol,
hydroxylation followed by oxidation of the pyrrolidine ring
to the lactam (200-oxo), hydroxylation and carboxylation of
the 40-methyl group, O-demethylation of the 40-methoxy
group, and demethylenation followed by O-methylation of
the 30, 40-methylenedioxy moiety [43].
A promising approach to elucidate metabolites of NPSs
includes in silico metabolite predictions, and human liver
microsome (HLM) and human hepatocyte incubations,
followed by analysis with high-resolution mass spec-
trometry (HRMS) and software-assisted data mining [44,
45]. Complete metabolic profiles are needed for 4-meth-
oxy-a-PVP to enable identification of intake and link
adverse effects to the causative agent. We evaluated
4-methoxy-a-PVP in silico metabolism predictions,
assessed metabolic stability with HLMs, and identified
metabolites after HLM and human hepatocyte incubations
followed by HRMS.
Fig. 1 Product ion mass spectrum of 4-methoxy-a-PVP and its fragmentation pattern




4-Methoxy-a-PVP HCl was purchased from Cayman
Chemicals (Ann Arbor, MI, USA) and diclofenac was
obtained from Toronto Research Chemicals (Toronto,
Canada). Fifty-donor purpose-pooled HLMs, 10-donor
purpose-pooled cryopreserved human hepatocytes, InVitro
Gro HT medium for thawing, and InVitro Gro KHB
(Krebs-Henseleit buffer) for washing and incubation were
acquired from BioreclamationIVT (Baltimore, MD, USA),
and NADPH-regenerating system (Solution A) and glu-
cose-6-phosphate dehydrogenase (Solution B) were pur-
chased from Corning Gentest (Woburn, MA, USA). LC–
MS grade water and formic acid were from Fisher Scien-
tific (Fair Lawn, NJ, USA), and LC–MS grade acetonitrile
from Sigma Aldrich (St. Louis, MO, USA).
In silico metabolite prediction
MetaSite software (v.5.0.3; Molecular Discovery, Pinner,
UK) was used to predict in silico 4-methoxy-a-PVP
metabolites. The structure of 4-methoxy-a-PVP was
imported into the software and predictions generated using
the CYP450 liver model, reactivity correction, 39 common
biotransformations, and a minimum mass threshold of
50 Da for predicted metabolites. The predicted sites of
metabolism are a consensus from liver CYP isoforms and
FMO3. The computational procedure considers both ther-
modynamic and kinetic factors. Potential metabolites were
assigned a probability score representing the likelihood of
being generated, with 100 % being the maximum score. In
addition, the top predicted in silico metabolite (100 %
probability score) was imported into the software to predict
second-generation metabolites.
Metabolic stability of 4-methoxy-a-PVP in HLMs
To investigate the metabolic stability of 4-methoxy-a-
PVP, 1 lmol/L drug was incubated with 50-donor pur-
pose-pooled HLMs. Water bath incubations were per-
formed on a Precision reciprocal shaking bath
(Winchester, VA, USA). The reaction mixture contained
780 lL purified water, 100 lL 0.5 mol/L potassium
phosphate buffer pH 7.4, 10 lL Solution B, and 10 lL
4-methoxy-a-PVP (100 lmol/L). Samples were vortexed
to homogenize the solutions, and 50 lL HLMs (20 mg
protein/mL suspension) were added to the mixture and
pre-incubated at 37 C for approximately 3 min. Organic
solvent percentage (methanol) was 1 %. The reaction was
initiated with the addition of 50 lL Solution A, and
100 lL samples were collected at 0, 3, 8, 13, 20, 30, 45,
and 60 min. The reaction was stopped with an equal
volume (100 lL) of cold acetonitrile. Samples were then
centrifuged at 15,0009g for 5 min at 4 C and subse-
quently stored at -80 C prior to analysis.
Incubation of 4-methoxy-a-PVP with cryopreserved
primary human hepatocytes
For the human hepatocyte experiments, 10 lmol/L
4-methoxy-a-PVP was incubated at 37 C with pooled
cryopreserved human hepatocytes. Hepatocytes were
incubated in a FormaTM Steri-CycleTM CO2 incubator from
Thermo Scientific (Fremont, CA, USA). The cells were
thawed in and washed with InVitro Gro HT medium and
centrifuged at 509g for 5 min at room temperature. The
supernatant was aspirated, and InVitro Gro KHB was
added to wash the hepatocytes again. After centrifugation
and removal of the supernatant, the cell pellet was re-
suspended in 2 mL buffer. Cell viability was assessed with
the Trypan blue exclusion method assuring[80 % viabil-
ity. The reaction mixture contained 250 lL 4-methoxy-a-
PVP in buffer (20 lmol/L) and 250 lL cell suspension,
yielding a final drug concentration of 10 lmol/L and final
cell concentration of 1 9 106 cells/mL. Samples (500 lL)
were collected at 0, 1, and 3 h based on HLM half-life
calculations, and the reaction stopped with 500 lL cold
acetonitrile. Specimens were stored at -80 C prior to
analysis. Diclofenac also was incubated as a positive
control for human hepatocyte functional viability.
Instrumentation
Liquid chromatography–high resolution mass spectrome-
try (LC-HRMS) was performed on a Thermo Scientific
NCS-3500RS Ultimate 3000 Binary Rapid system cou-
pled to a Thermo Scientific QExactive mass spectrometer
(Thermo Scientific). The Ultimate 3000 RSLCnano sys-
tem consisted of a degasser, a tertiary loading pump, a
binary eluting pump, a column oven, and an RS
Autosampler. The QExactive contained a heated electro-
spray ionization source (HESI-II) and was operated in
positive ionization mode. The spray voltage was 3 kV,
capillary temperature 350 C, heater temperature 425 C,
S-lens RF level 50, sheath gas flow rate 50, auxiliary gas
flow rate 13 and sweep gas 3 (manufacturer’s units).
Nitrogen was used for spray stabilization, for collision-
induced dissociation experiments in the HCD cell, and as
the damping gas in the C-trap. The instrument was cali-
brated in the positive and negative modes every 25 h.
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LC-HRMS for HLM samples
Chromatographic separation of HLM samples, diluted
100-fold with mobile phase A (0.1 % formic acid in water),
was achieved with an Accucore C18 column (2.6 lm,
100 9 2.1 mm) and C18 guard cartridge (4 9 2.0 mm) with
a 0.4 mL/min flow rate at 35 C. Gradient elution was per-
formed with 2 % B (0.1 % formic acid in acetonitrile) for
2 min, increased to 10 % B at 10 min, then ramped to 30 %
B at 14 min, from 30 to 95 % in 2 min, held at 95 % for
1 min, and returned to initial conditions over 1 min. A 2-min
equilibration followed, yielding a total run time of 20 min.
Full scan data-dependent MSMS (ddMS2) data were
collected from m/z 100 to 600 at 70,000 resolution with
automatic gain control (AGC) target 1.0 9 106, and max-
imum injection time 250 ms. Dd MS2 scans were triggered
at the apex of the peak (3–8 s) when an underfill ratio of
5 % was reached (intensity 8.3 9 104) for the 5 most
intense peaks per cycle (TopN of 5). MS scans were
acquired at a resolution of 17,500 with AGC of 2 9 105,
maximum injection time of 120 ms, and stepped normal-
ized collision energy (NCE) 50 ± 30 %.
LC-HRMS for human hepatocytes
Hepatocyte samples were diluted fivefold with mobile phase
A and chromatographically separated using a Synergi 4
Hydro-RP column (80A˚, 150 9 2 mm) and C18 guard
cartridge (4 9 2.0 mm) within 30 min at 0.4 mL/min flow
rate. Initial conditions (2 % B) were held for 2 min,
increased to 95 % B for 18 min, held at 95 % B for 5 min,
and returned to initial conditions over 1 min. A 4-min
equilibration followed, yielding a total run time of 30 min.
Hepatocytes incubations were analyzed with three dif-
ferent MS methods: full scan and ddMS2, with (1) and
without (2) an inclusion list of predicted metabolites, and
with a full scan and all-ion-fragmentation (AIF) method
(3). Full scan and ddMS2 data (without an inclusion list)
were acquired as previously described for HLM samples.
In addition, an inclusion list was generated by MetaSite
software based on its in silico metabolism predictions and
imported into the full scan ddMS2 acquisition method.
DdMS2 scans were triggered if the precursor ions from the
inclusion list were detected above 8.3 9 104 intensity
threshold. To identify potential unexpected metabolites,
full scan and AIF data were acquired. AIF experiments
were performed at 35,000 resolution over a scan range
of m/z 100–600, with AGC target 5 9 105, maximum
injection time of 120 ms, and a stepped NCE 50 ± 30 %.
Data analysis
In vitro microsomal half-life (T1/2) and microsomal
intrinsic clearance (CLint, micr) of 4-methoxy-a-PVP were
calculated on the model described by Baranczewski et al.
[46]. This microsomal intrinsic clearance was then scaled
to whole liver dimensions to calculate the intrinsic clear-
ance (CLint) by multiplying two factors: the content of
microsomal protein/g liver tissue (*45 mg/g) and liver
weight/kg body weight (*20 g/kg), according to McNaney
et al. [47]. Human hepatic clearance (CLH) and extraction
ratio were calculated [46] without consideration of plasma
protein binding.
Mass spectra acquired by the QExactive were analyzed
with WebMetaBase software (v.2.0.2, Molecular Dis-
covery) for metabolite candidates in the HLM and hepa-
tocyte incubations. Raw data were submitted as a batch,
which included a substrate (parent compound, 4-methoxy-
a-PVP) structure mol file, a blank file (mobile phase), a
substrate file (neat standard) to analyze the substrate
fragmentation pattern, and raw data files for each incu-
bation time point for hepatocyte incubations (t = 0, 1,
3 h) and for HLMs (t = 0, 3, 8, 13, 20, 30, 45, 60 min).
Processing parameters for hepatocyte incubations were as
follows: ‘‘hepatocyte metabolic system’’; retention time
window 2–25 min; chromatogram, MS, and MS/MS aut-
ofilter thresholds of 0.98; same peak tolerance of 0.010;
three metabolite generations, minimum metabolite gen-
eration mass of 50 Da, and expected metabolites were
rescue enabled (selects peaks with an equivalent m/z to a
known metabolite regardless of peak area, provided there
is MS2 data associated with the peaks). For the HLM
incubations, similar processing parameters were chosen,
except the metabolic system selected was HLMs and the
retention time window was 2–18 min due to the different
chromatography. The software auto-detects chromato-
graphic peaks related to the parent compound and its
metabolites, proposes potential structures based on frag-
mentation patterns for each detected peak and Markush
structures (chemical structures with functional groups
highlighted based on site reactivity), and ranks potential
structures compatible with extracted fragment informa-
tion. Structures of potential metabolite candidates were
assigned based on retention times, mass shift between
theoretical mass and observed mass (\5 ppm), peak
abundance and fragmentation pattern. Metabolites were
thoroughly examined against literature reports of struc-
turally similar compounds and were eventually compared
to the in silico predictions.
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Results
In silico metabolite prediction
Eleven predicted in silico metabolites were generated with
MetaSite software and are summarized in Table 1
(scores[ 20 %), with three second-generation metabolites
predicted from the highest ranked in silico metabolite. The
top three metabolites predicted in silico were the O-
demethylated metabolite, the metabolite hydroxylated at
C50 position, and the metabolite hydroxylated at the phenyl
ring. Using the top predicted first-generation metabolite (4-
hydroxy-a-PVP), three second-generation metabolites were
predicted including the aromatic hydroxylated metabolite,
the metabolite hydroxylated at C50 position, and the
metabolite resulting from ring opening and oxidation
(Table 1).
Metabolic stability assessment with HLMs
4-Methoxy-a-PVP exhibited an in vitro T1/2 of
79.7 ± 1.3 min in HLMs, with a microsomal intrinsic
clearance CLint, micr of 8.7 lL min
-1 mg-1 and intrinsic
clearance CLint of 8.2 mL min
-1 kg-1. Hepatic clearance
was calculated to 5.8 mL min-1 kg-1 and the extraction
ratio was 0.29.
Identification of HLM metabolites
In the HLM samples, the O-demethylated metabolite (M3
in the hepatocyte samples) was the only metabolite
detected. Peak areas increased from the 20 to 60 min
incubation times.
Metabolite profiling with human hepatocytes
Diclofenac (positive control) and its metabolites, 4-hy-
droxydiclofenac and diclofenac b-D-acyl glucuronide, were
observed in the hepatocyte samples confirming hepatocyte
metabolic activity. Accurate full scan and product ion
spectra were obtained and thoroughly data-mined, identi-
fying eleven 4-methoxy-a-PVP metabolites (Table 2) with
mass measurement errors \1.5 ppm. Metabolites eluted
between 4.9 and 13.8 min with 4-methoxy-a-PVP parent at
9.1 min (Table 2). Ten phase I metabolites (M1–M7, M9–
M11) and one phase II metabolite (M8) were identified in
the hepatocyte samples. In the 1-h sample, M1, M3–M7,
and M9 were the only metabolites detected with 91.0 % of
Table 1 In silico predicted metabolites for 4-methoxy-a-PVP in decreasing order based on score
First 
Generation 4-methoxy-α-PVP P1
a P2 P3 P4 P5
Reaction
Mass (Da)
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Second generation metabolites were generated by importing first generation metabolites with scores of 100 % into the in silico software (only P1
had a score of 100 %)
a Identified in 3 h human hepatocyte incubation
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4-methoxy-a-PVP unchanged. All metabolites were found
in the 3-h sample with 78.7 % of the parent compound
remaining. Consistent with ongoing metabolism, 4-meth-
oxy-a-PVP peak areas decreased during incubation while
in general metabolite peak areas increased from 1 to 3 h
incubation. The metabolic reactions observed included: O-
demethylation (M3), O-demethylation ? N-dealkylation
(M1), O-demethylation ? ketone reduction (M2), hydrox-
ylation (M4, M6), pyrrolidine ring opening ? hydroxyla-
tion (M5), ketone reduction (M7), carbonylation (M11),
aliphatic N-oxidation (M9), and iminium ion formation
(M10). One glucuronide also was noted (M8); however, a
product ion mass spectrum for M8 was not obtained, as the
intensity threshold criterion was not met. Based on
observed peak areas, M3 was the most intense metabolite
in hepatocyte incubations, followed by M6 and M7.
All metabolites were identified with full scan and
ddMS2, with the exception of M8. This glucuronidated
metabolite was identified with our full scan and dd-MS2
with the in silico generated inclusion list. Other than M8,
this acquisition method did not detect any additional
metabolites and only found 5/10 metabolites (M3, M4, M6,
M7, and M11) identified with full scan and ddMS2 . The
full scan and AIF method did not detect any additional
unexpected metabolites. Compared to full scan and ddMS2,
the full scan and AIF did not identify M5 (pyrrolidine ring
opening ? hydroxylation), the lowest prevalence metabo-
lite other than M8.
Discussion
A variety of different product ions were observed for
4-methoxy-a-PVP (Fig. 1), with m/z 121 the most intense
fragment ion at the given collision energy conditions. The
base peak is generated by cleavage between the b-keto
(C10) and aromatic ring. Cleavage of the bond between the
b-keto (C10) and alpha (C20) carbon generated the next
highest intensity ions at m/z 126 and 135, similar to
cleavage that was previously reported for a-PVP [37].
Fragmentation of the bond between the pyrrolidine ring
and alpha carbon (C20) produced m/z 191 and 72 ions.
Other distinct product ions included m/z 219 (loss of C3H7
radical) and 84. The unique fragmentation pattern of
4-methoxy-a-PVP was used for metabolite structure
elucidation.
Identification of O-demethylated metabolites
4-Hydroxy-a-PVP (M3), the product of O-demethylation
of the 4-methoxy moiety, was the most intense metabolite
in the HLMs and 1 and 3 h hepatocyte samples (Table 2).
Figure 2 illustrates the product ion spectra for all O-
demethylated metabolites. M3 product ion mass spectrum
showed three distinct fragments of the precursor 4-meth-
oxy-a-PVP molecule (m/z 126, 72, and 84) suggesting no
modifications to the pyrrolidine ring and aliphatic chain of
the molecule. The characteristic fragments of M3 included
Table 2 4-Methoxy-a-PVP phase I metabolites identified after incubation with human hepatocytes, sorted by retention time (RT). Rank was
based on mass spectrometric peak areas. Fragments are expressed in nominal mass






Characteristic fragments MS % peak
areas
Ranking
1 h 3 h 1 h 3 h
M1 O-Demethylation ? N-
dealkylation
4.87 C11H15NO2 194.1177 0.52 135, 107, 58 2.2e
7 2.9e7 4 6
M2 Ketone reduction ? O-
demethylation
7.26 C15H23NO2 250.1800 0.80 189, 232, 107, 70 – 1.3e
7 – 9
M3 O-Demethylation 7.48 C15H21NO2 248.1643 0.81 107, 126, 121, 72, 177 4.7e
8 7.5e8 1 1
M4 Hydroxylation 8.51 C16H23NO3 278.1748 1.08 121, 142, 135, 191 1.2e
7 2.7e7 6 7
M5 Pyrrolidine ring
opening ? hydroxylation
8.65 C16H25NO3 280.1906 0.36 121, 190, 262, 148, 135,
144
1.4e7 1.2e7 5 10
M6 Di-hydroxylation 8.78 C16H23NO4 294.1699 0.31 121, 87, 140, 276, 135,
191
8.0e7 1.9e8 2 2
M7 Ketone reduction 8.96 C16H25NO2 264.1957 0.38 246, 203, 188, 121, 175,
72
4.8e7 1.1e8 3 3
M9 Aliphatic N-oxidation 9.81 C16H23NO3 278.1749 0.72 126, 86, 135, 163, 121 9.3e
6 1.8e7 7 8
M10 Iminium ion formation 11.48 C16H21NO2 260.1644 1.54 175, 86, 121, 70 – 3.6e
7 – 5
M11 Carbonylation 13.83 C16H21NO3 276.1593 0.36 140, 98, 121, 135, 69, 191 – 3.9e
7 – 4
Parent 9.10 C16H23NO2 262.1798 1.53 121, 126, 135. 191, 84,
163, 219, 72, 70
6.6e9 4.4e9 – –
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Fig. 2 Product ion mass spectra
and assigned fragmentation
patterns for 4-methoxy-a-PVP
metabolites generated by O-
demethylation. a 4-Hydroxy-a-
PVP M3, b O-demethylated and
ketone reduced metabolite M2,
and c the O-demethylated and
N-dealkylated metabolite M1
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metabolites: a the di-
hydroxylated metabolite on the
pyrrolidine ring M6, b the
monohydroxylated metabolite
on the pyrrolidine ring M4, and
c the ring opening and
hydroxylated metabolite M5.
The exact location of the di-
hydroxylated metabolite is
unknown; however, the position
of the hydroxyl group at the 200
in M4 is suggested based on
previously identified a-
pyrrolidine metabolites
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m/z 107 and 121 indicating O-demethylation at the meth-
oxy group and subsequent formation of the tropylium ion
and bond cleavage between the b-keto (C10) and alpha
(C20) carbons. Further reduction of M3 at the keto moiety
yielded M2 at m/z 250. M2 product ion spectrum showed a
characteristic m/z 189 fragment produced by cleavage of
the carbonyl and terminal C3H7 radical, and a m/z 232
fragment from loss of water. In addition, N-dealkylation of
the pyrrolidine ring of M3 yielded M1. This metabolite
product ion spectrum showed characteristic fragments m/z
135, 107, and 58 suggesting modifications to the pyrro-
lidine ring and 4-methoxy moiety.
Identification of hydroxylated metabolites
Three hydroxylated metabolites, one monohydroxylated
(M4), one di-hydroxylated (M6) and one pyrrolidine ring
opening and hydroxylated metabolite (M5) were identified.
Figure 3 illustrates the product ion spectra for all hydrox-
ylated metabolites. Hydroxylations occurred at the pyrro-
lidine ring, as three characteristic fragments from
4-methoxy-a-PVP were identified in each metabolite (m/
z 121, 135, and 191). M6 was the second most intense peak
after 1 and 3 h incubations showing fragments at m/z 158,
140, 276, 98, and 87, suggesting di-hydroxylation at the
pyrrolidine ring. M4 showed distinct fragments including
m/z 142, 100, and 70 supporting a monohydroxylation on
the pyrrolidine ring. The exact position of the hydroxyl
group is unclear, although, previous metabolism studies
identified 200-OH-a-PVP in the structurally similar com-
pound a-PVP [37, 40, 41]. It is expected that similar
metabolism could be observed with M4. The last identified
hydroxyl metabolite (M5) was the product of the pyrro-
lidine ring opening and hydroxylation on the terminal end,
similar to what was reported for a-PVP [48]. Characteristic
fragments were m/z 262, 144, and 219.
Metabolite generated by ketone reduction
The third most prevalent metabolite in the 1 and 3 h hep-
atocyte samples was the ketone reduced metabolite, M7
(Fig. 4). The base peak m/z 246 resulted from the loss of
water. Other characteristic fragments included m/z 203,
188, 175, and 121 and 72 as observed with the precursor
molecule.
Other identified metabolites
Two metabolites were products of oxidation reactions
(M11 and M9) (Fig. 5). M11 was the result of carbonyla-
tion of the pyrrolidine ring, a common biotransformation
for a-pyrrolidinophenones [43]. Characteristic fragments of
this late eluting compound included m/z 140, 98, 86, 121,
Fig. 4 Product ion mass spectrum and fragmentation pattern for the metabolite generated by ketone reduction M7






a carbonylation of the
pyrrolidine ring M11,
b aliphatic N-oxidation M9, and
c iminium ion formation M10.
The location of the carbonyl
moiety at the 200-position is
based on previously identified
a-pyrrolidine lactams
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and 191. The amide is less basic than the tertiary amine in
the parent compound and, therefore, is less likely to be
protonated and as water soluble as the parent. The N-oxide
metabolite (M9) also eluted after the parent compound,
with the simultaneous appearance of m/z 126 and 135 and
an m/z 86 fragment that was not observed in the mono-
hydroxylated metabolite (M4), thus suggesting this oxida-
tion reaction. Other distinct fragments included m/z 163,
121, and 191. In addition to these oxidative metabolites,
the formation of the iminium ion was proposed (M10). This
compound also was predicted in silico (P7). Fragments
included m/z 175, 121, 86, 98,160, and 70. The m/z 70
fragment suggests the formation of an iminium ion at the
pyrrolidine ring; otherwise fragment m/z 72 should be
observed as in the parent compound (Fig. 1) after cleavage
of the pyrrolidine ring.
Prevalence of 4-methoxy-a-PVP metabolites
Most likely, the most intense MS peak areas observed
in vitro will be the major 4-methoxy-a-PVP metabolites
in vivo, or the precursors of second-generation in vivo
metabolites. The most abundant metabolite in the hepato-
cyte samples at both 1 and 3 h was 4-hydroxy-a-PVP [M3,
retention time (RT) 7.48 min], resulting from O-demethy-
lation. This also was the only metabolite observed in the
HLM samples and the highest predicted in silico metabo-
lite. The next most abundant hepatocyte metabolites were
di-hydroxylations of the pyrrolidine ring (M6, RT
8.78 min) and ketone reduction to the corresponding
alcohol (M7, RT 8.96 min). Other major metabolites of
4-methoxy-a-PVP may exist and may have been missed in
human hepatocyte and HLM incubations due to short
incubation times, and the long half-life of parent 4-meth-
oxy-a-PVP. Based on our results, 4-hydroxy-a-PVP is the
major metabolite of 4-methoxy-a-PVP and could be used
in combination with the parent compound as potential
markers. A metabolic pathway for 4-methoxy-a-PVP in
hepatocytes is illustrated in Fig. 6.
Metabolic stability assessment in HLMs
4-Methoxy-a-PVP exhibited a long half-life
(79.7 ± 1.3 min) in vitro, identified by the slow 9 and
21.3 % decrease of parent compound at 1 and 3 h in the
hepatocyte samples, respectively. Based on the intrinsic
clearance, extraction ratio and half-life observed in this
study, 4-methoxy-a-PVP is predicted to be slowly metab-
olized. Low clearance compounds typically have
CLint\ 15 mL min
-1 kg-1 [47] and extraction ratios\0.3
[49]. It is important to note that predicted hepatic clearance
can vary among individuals based on enzymatic
polymorphisms.
Comparison with other synthetic cathinones
In general, 4-methoxy-a-PVP followed the metabolic pat-
terns identified in other structurally similar synthetic
cathinones, i.e. multiple hydroxylation products, carbony-
lation, ring opening and oxidation reactions, ketone
reduction, and O-demethylation [43]. The major metabolic
pathway identified in our study was O-demethylation of the
4-methoxy group, similar to MOPPP (a 4-methoxy-a-
pyrrolidinophenone with a three-carbon alkyl chain) in
HLMs by Springer et al. [36].
Several studies investigated the metabolism of a-PVP,
the closest analog to 4-methoxy-a-PVP. An in vivo study
examining rat urine following a 20 mg/kg a-PVP dose
reported multiple hydroxylation products of a-PVP, car-
bonylation of the 20-position of the pyrrolidine ring, ring
opening and oxidation reactions, as well as degradation of
the pyrrolidine ring to the corresponding primary amine
[37]. For a-PVP and a-PBP in authentic human urine
specimens, Uralets et al. [42] reported N-dealkylation to
the primary amine metabolite that subsequently underwent
ketone reduction. The authors suggested that the pyrro-
lidine ring hinders direct ketone reduction. No information
was provided about the time of urine collection and how
long after dosing the specimens were collected. However,
ketone reduction was identified by Tyrkko et al. [39] while
investigating the phase I metabolites of a-PVP in vitro
using HLMs and in authentic human urine. Similarly,
Shima et al. [40] found that the two major metabolic
pathways of a-PVP identified in human urine were the
reduction of the ketone to the corresponding alcohol and
the carbonylation of the 20-position of the pyrrolidinophe-
none ring to produce the 200-oxo metabolite, which was also
confirmed by Namera et al. [41]. Alpha-PVP and a-PBP do
not contain the 4-methoxy moiety, and therefore, cannot
produce O-demethylated metabolites.
We identified all a-PVP metabolic biotransformations,
as discussed above, in our study of the novel 4-methoxy-a-
PVP, with the exception of N-dealkylation of the pyrro-
lidine ring to the corresponding primary amine. Since
formation of the primary amine metabolite was one of the
major pathways for a-PVP, we carefully checked all our
raw data, and although we did not identify this metabolite,
we did find the metabolite resulting from degradation of the
pyrrolidine ring in combination with O-demethylation
(M1). In agreement with Tyrkko et al. [39] and Shima et al.
[40], we also identified a metabolite resulting from direct
reduction of the ketone moiety for 4-methoxy-a-PVP (M7)
as also observed for a-PVP. Ketone reduction and car-
bonylation of the pyrrolidine ring were ranked 3rd and 4th
among the most prevalent metabolites, respectively.
It is important to note that although incubation with
hepatocytes reflects liver metabolism, it cannot reflect
Forensic Toxicol (2016) 34:61–75 71
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additional processes involved in drug elimination including
extrahepatic metabolism, enterohepatic circulation, and
renal filtration, re-absorption, and secretion. In addition,
distribution processes can alter parent and metabolite pat-
terns and concentrations that hepatocytes cannot simulate.
Metabolites identified in these experiments may be present
Fig. 6 Proposed metabolic pathways for 4-methoxy-a-PVP in human hepatocytes. Position of di-hydroxylation on the pyrrolidine ring in M6 is
unknown and represented with Markush structures
72 Forensic Toxicol (2016) 34:61–75
123
in human urine and blood after 4-methoxy-a-PVP intake;
however, it is important to confirm these metabolites in
authentic specimens as hepatocytes only reflect one aspect
of drug elimination.
In silico prediction of 4-methoxy-a-PVP metabolites
In silico metabolite prediction software was used to pre-
dict 4-methoxy-a-PVP metabolic candidates and evaluate
them against metabolites identified in vitro. Eleven phase
I metabolites with a probability score[20 % were pre-
dicted in silico, while ten phase I metabolites were
identified in the 3 h hepatocyte samples. Three in silico
metabolites ([20 %) matched metabolites identified in the
3 h hepatocyte samples, namely M3, which corresponds
to P1 scoring 100 % in silico and also the predominant
hepatocyte metabolites, M10 (?P7) and M11 (?P8)
(Table 1). Metabolites resulting from hydroxylation of the
pyrrolidine ring (M4) and ketone reduction (M7) also
were predicted in silico, although scores were less than
20 % (19.1 and 8.2 %, respectively). Five hepatocyte
biotransformations were not predicted in silico; however,
these metabolites involved combinations of phase I bio-
transformations, which the software does not readily
predict. Manufacturers suggest analyzing the top pre-
dicted metabolites (100 % scores) in the software in order
to identify potential second-generation metabolites. In our
case, none of the predicted second-generation metabolites
were identified in vitro in this study; a possible reason
might be the low clearance of the parent compound.
Although in silico prediction software has limitations, it is
a valuable investigative tool for metabolite identification,
especially for novel psychoactive substances. Limited
information for these compounds exists; thus in silico
prediction software can aid in developing a chromato-
graphic method as it suggests metabolites that may be less
polar than the parent. In addition, the software also can be
used to import an inclusion list for MS acquisition
methods.
Conclusions
4-Methoxy-a-PVP followed the metabolic patterns com-
parable to other pyrrolidinophenones, including O-
demethylation, ketone reduction, multiple hydroxylation
products, ring opening and oxidation reactions, N-dealky-
lation, and carbonylation to the corresponding lactam. The
combination of different HRMS acquisition methods
proved useful for identifying potential metabolites, as these
are the first data identifying 4-methoxy-a-PVP metabolites
that are good targets for documenting drug intake in
forensic and clinical investigations. Based on our results,
4-hydroxy-a-PVP, the predominant metabolite, and the
parent compound are good markers to identify consump-
tion. This study demonstrated the applicability of using
in vitro techniques coupled with HRMS methods to elu-
cidate the metabolic profiles of emerging NPSs and com-
parison with in silico metabolite predictions. It is necessary
to elucidate the metabolic pathways of these NPSs to
enable linkage to adverse effects and recent intake.
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